Advertisement
Australia markets closed
  • ALL ORDS

    7,817.40
    -81.50 (-1.03%)
     
  • ASX 200

    7,567.30
    -74.80 (-0.98%)
     
  • AUD/USD

    0.6425
    -0.0000 (-0.01%)
     
  • OIL

    82.72
    -0.01 (-0.01%)
     
  • GOLD

    2,395.70
    -2.30 (-0.10%)
     
  • Bitcoin AUD

    101,028.65
    +3,398.49 (+3.48%)
     
  • CMC Crypto 200

    1,334.09
    +21.46 (+1.66%)
     
  • AUD/EUR

    0.6020
    -0.0011 (-0.19%)
     
  • AUD/NZD

    1.0891
    +0.0017 (+0.15%)
     
  • NZX 50

    11,796.21
    -39.83 (-0.34%)
     
  • NASDAQ

    17,314.33
    -79.99 (-0.46%)
     
  • FTSE

    7,853.51
    -23.54 (-0.30%)
     
  • Dow Jones

    37,976.38
    +201.00 (+0.53%)
     
  • DAX

    17,754.98
    -82.42 (-0.46%)
     
  • Hang Seng

    16,224.14
    -161.73 (-0.99%)
     
  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     

Why Shares of Allogene Therapeutics, Beam Therapeutics, Intellia Therapeutics, and Schrödinger Are Volatile This Week

Why Shares of Allogene Therapeutics, Beam Therapeutics, Intellia Therapeutics, and Schrödinger Are Volatile This Week

After the Food and Drug Administration paused Allogene Therapeutics' (NASDAQ: ALLO) clinical trials last week, the stock was crushed. The FDA's intervention appeared to spur trading by ARK Invest in Beam Therapeutics (NASDAQ: BEAM), Intellia Therapeutics (NASDAQ: NTLA), and Schrödinger (NASDAQ: SDGR).